1. Bailey DL, Antoch G, Bartenstein P, Barthel H, Beer AJ, Bisdas S, Bluemke DA, Boellaard R, Claussen CD, Franzius C, Hacker M, Hricak H, la Fougere C, Guckel B, Nekolla SG, Pichler BJ, Purz S, Quick HH, Sabri O, Sattler B, Schafer J, Schmidt H, van den Hoff J, Voss S, Weber W, Wehrl HF, Beyer T. Combined PET/MR: The Real Work Has Just Started. Summary Report of the Third International Workshop on PET/MR Imaging; February 17-21, 2014, Tubingen, Germany. Molecular Imaging and Biology 2015; 17:297-312.
  2. Bailey DL, Pichler BJ, Guckel B, Barthel H, Beer AJ, Bremerich J, Czernin J, Drzezga A, Franzius C, Goh V, Hartenbach M, Iida H, Kjaer A, la Fougere C, Ladefoged CN, Law I, Nikolaou K, Quick HH, Sabri O, Schafer J, Schafers M, Wehrl HF, Beyer T. Combined PET/MRI: Multi-modality Multi-parametric Imaging Is Here. Molecular Imaging and Biology 2015; 17:595-608.
  3. Baur B, Kramer L, Winter G, Linden M, Beer A, Solbach C. Zr-89-, Y-90-and Lu-177-labeling and biological testing of mesoporous silica based nanoparticles. Journal of Nuclear Medicine 2015; 56.
  4. Baur B, Scheel W, Ruckgaber J, Beer A, Solbach C. Development of an automated module for the separation of Zr-89 from irradiated Y-89 foils. Journal of Nuclear Medicine 2015; 56.
  5. Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kubler H, Haberhorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M. Evaluation of Hybrid Ga-68-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Journal of Nuclear Medicine 2015; 56:668-674.
  6. Franz D, Karampinos DC, Rummeny EJ, Souvatzoglou M, Beer AJ, Nekolla SG, Schwaiger M, Eiber M. Discrimination Between Brown and White Adipose Tissue Using a 2-Point Dixon Water Fat Separation Method in Simultaneous PET/MRI. Journal of Nuclear Medicine 2015; 56:1742-1747.
  7. Hardiansyah D, Guo W, Kletting P, Muller B, Mottaghy F, Glatting G. The variability of predicted area under the curves for different degrees of noise in PET measurements for treatment planning in peptide-receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42:S10-S10.
  8. Hardiansyah D, Guo W, Kletting P, Muller B, Mottaghy F, Glatting G. Investigation on the number of PET measurements needed for accurate prediction of therapeutic biodistribution in PRRT. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42:S6-S7.
  9. Hardiansyah D, Maass C, Attarwala A, Kletting P, Muller B, Mottaghy F, Glatting G. Prediction accuracy of therapeutic biodistribution in peptide receptor radionuclide therapy: Role of patient-based treatment planning. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42:S9-S10.
  10. Kaltenbach TEM, Graeter T, Mason RA, Kratzer W, Oeztuerk S, Haenle MM, Gruener B, Gottstein M. Determination of vitality if liver lesions by alveolar echinococcosis Comparison of parametric contrast enhanced ultrasound (SonoVue (R)) with quantified F-18-FDG-PET-CT. Nuklearmedizin-Nuclear Medicine 2015; 54:43-49.
  11. Kletting P, Maass C, Reske S, Beer AJ, Glatting G. Physiologically Based Pharmacokinetic Modeling Is Essential in Y-90-Labeled Anti-CD66 Radioimmunotherapy. Plos One 2015; 10.
  12. Kletting P, Schimmel S, Hanscheid H, Luster M, Fernandez M, Nosske D, Lassmann M, Glatting G. The NUKDOS software for treatment planning in molecular radiotherapy. Zeitschrift Fur Medizinische Physik 2015; 25:264-274.
  13. Kletting P, Schuchardt C, Kulkarni H, Sayeg M, Wiesalla S, Winter G, Singh A, Baum R, Beer A. Quantifying the Effect of Peptide Amount on the Biologically Effective Dose for Therapy using Lu-177 Labeled PSMA Ligands. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42:S60-S60.
  14. Maass C, Kletting P, Bunjes D, Mahren B, Beer AJ, Glatting G. Population-Based Modeling Improves Treatment Planning Before Y-90-Labeled Anti-CD66 Antibody Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals 2015; 30:285-290.
  15. Maass C, Kletting P, Hardiansyah D, Mahren B, Bunjes D, Beer A, Glatting G. Improved treatment planning in radioimmunotherapy with 90Y-anti-CD66 antibody using population based modelling. European Journal of Nuclear Medicine and Molecular Imaging 2015; 42:S259-S260.
  16. Maass C, Sachs J, Hardiansyah D, Kletting P, Mottaghy FM, Glatting G. Optimal sampling schedule: accurate estimation of time-integrated activity coefficients in peptide receptor radionuclide therapy (PRRT). European Journal of Nuclear Medicine and Molecular Imaging 2015; 42:S36-S37.
  17. Malik N, Baur B, Winter G, Reske SN, Beer AJ, Solbach C. Radiofluorination of PSMA-HBED via (AlF2+)-F-18 Chelation and Biological Evaluations In Vitro. Molecular Imaging and Biology 2015; 17:777-785.
  18. Masood M, Iqbal SZ, Asi MR, Malik N. Natural occurrence of aflatoxins in dry fruits and edible nuts. Food Control 2015; 55:62-65.
  19. Rauscher I, Beer AJ, Schaeffeler C, Souvatzoglou M, Cronlein M, Kirchhoff C, Sandmann G, Furst S, Kilger R, Herz M, Ziegler S, Schwaiger M, Eiber M. Evaluation of F-18-Fluoride PET/MR and PET/CT in Patients with Foot Pain of Unclear Cause. Journal of Nuclear Medicine 2015; 56:430-435.
  20. Reske S, Glatting G, Gottstein M. Detection of relapsing protate cancer with PET/CT: noninferiority of Ga-68-labeled PSMA-binding peptide to C-11 choline in extraprostatic relapse. Journal of Nuclear Medicine 2015; 56.
  21. Riepe M, Walther B, Vomend C, Beer A. Drug-induced cerebral glucose metabolism resembling Alzheimer's Disease: a case study. Zeitschrift Fur Gerontologie Und Geriatrie 2015; 48:44-44.
  22. Riepe MW, Walther B, Vonend C, Beer AJ. Drug-induced cerebral glucose metabolism resembling Alzheimer's Disease: a case study. Bmc Psychiatry 2015; 15.
  23. Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. Journal of Controlled Release 2015; 199:145-155.